R
Reactive Biosciences (Formerly Boragen)
Refining the unique characteristics of boron to deliver solutions that make a difference
About Reactive Biosciences (Formerly Boragen)
ReactiveBio operates at the forefront of pharmaceutical innovation, leveraging a cutting-edge boron-based discovery platform to develop groundbreaking medicines. The company primarily serves pharmaceutical companies and research institutions, focusing on creating impactful treatments that can significantly improve patients' lives. ReactiveBio's business model revolves around strategic partnerships, where it collaborates with other entities to accelerate the discovery and development of new drugs. Revenue is generated through these partnerships, as well as through licensing agreements and potential future sales of proprietary medicines. The market ReactiveBio operates in is highly specialized, targeting the niche but critical area of boron chemistry in drug discovery. By combining boron chemistry with computationally enabled structure-based drug design, ReactiveBio aims to push the boundaries of precision medicine. The company is driven by a cohesive team of passionate innovators dedicated to making a lasting impact on healthcare.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Jun 2023 | $4M | — | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Sep 2022 | $24M | $94M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Reactive Biosciences (Formerly Boragen) is 50 monthly website visits, down 28.6% over the last three months. Reactive Biosciences (Formerly Boragen)'s team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Reactive Biosciences (Formerly Boragen) in the Durham ecosystem
The Reactive Biosciences (Formerly Boragen) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US National Institute of Allergy and Infectious Diseases
Small Business Innovation Research
Other known investors4 additional known investors
Massachusetts Institute of Technology
Penn State University
Stanford University
ARCH Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reactive Biosciences (Formerly Boragen) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reactive Biosciences (Formerly Boragen)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









